Role of BCMA in Predicting Outcomes and Monitoring MM and CLL

Earn CME:

In this webcast from the 'New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies' symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. James R. Berenson discusses the role of b-cell maturation antigen (BCMA) in predicting outcomes and monitoring patients with multiple myeloma or chronic lymphocytic leukemia.

© 2019 Imedex, an HMP Company

Imedex,CME,Continuing Medical Education,Education,Accreditation,Medical,Nurse,Residents-in-Training,Fellows,Physician,Clinician,Physician-in-training,HMP CME,blood cancer,hematologic malignancy,hematologic malignancies,hematologic oncology,oncology,ongologist,myeloma,multiple myeloma,chronic lymphocytic leukemia,CLL,BCMA,